Catalyst Dossier · compiled by CeliA 🧫

Galderma Group AG/ADR (GDERF)

Biotechnology · market cap $48.7B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Galderma Group AG (GDERF) is a dermatology-focused company with a market capitalization of approximately $48.7 billion, operating across aesthetics, dermatological skincare, and therapeutic dermatology. Its pipeline spans multiple Phase 2 and Phase 3 programs including botulinum toxin formulations for aesthetic indications, nemolizumab for moderate-to-severe atopic dermatitis, and several other dermatology assets. No upcoming catalysts are currently scheduled in the public calendar, and financial details including cash, revenue, and analyst coverage are not available in the provided data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
botulinum toxin	Phase 3	Lateral Canthal Lines
Nemolizumab	Phase 3	Moderate-to-Severe Atopic Dermatitis
Botulinum Toxin Type A	Phase 2	Glabellar Frown Lines
Metvix® cream	Phase 3	Basal Cell Carcinoma
Adapalene	Phase 2	Acne Scars
CD 2027	Phase 2	Plaque-type Psoriasis
botulinum toxin neuromodulator	Phase 3	Glabellar Frown Lines (GL)
CD07805/47 gel	Phase 3	Rosacea
QM1114-DP	Phase 3	Glabellar Frown Lines

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GDERF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.